South Australia is the only Australian jurisdiction with a licensing regime in place allowing exploration for natural hydrogen projects and the rural town of Elliston could hold the answer to storing the element.
BioNTech receives exclusive licenses from DualityBio for two investigational antibody-drug conjugate assets (DB-1303 and DB-1311) directed against targets.
BioNTech to receive exclusive worldwide license from OncoC4 to develop and commercialize its anti-CTLA-4 monoclonal antibody candidate, ONC-392BioNTech and.